Author/Editor		Kornhauser-Cerar, L; Anžič, J
Title		Anemija nedonošenčka - zdravljenje z rekombinantnim humanim eritropoetinom kot alternativa transfuziji?
Translated title		Anaemia of prematurity - treatment with recombinant human erythropoietin as an alternative to transfusion?
Type		članek
Source		Slov Pediatr
Vol. and No.		Letnik 1, št. 1
Publication year		1994
Volume		str. 34-9
Language		slo
Abstract		Technological advances, such as recombinant DNA technology, have resulted in the production of recombinant human erythropoietin for therapeutic purposes in correcting anaemia. Simultaneously they have allowed new insights into the chemistry, production and action of the hormone and other growth factors in haematopoiesis. In recent years the focus of research into the mechanism of erythropoietin function has been on the interactions between the hormone and its target - erythroid progenitor cells, the reaction being mediated through specific cell surface receptors. Replacement therapy with recombinant human erythropoietin is very beneficial in the treatment of anaemia associated with chronic renal failure, as has been well established by several multicentre clinical trials. In addition, the application of this hormone appears to be useful in other types of anaemia, such as in rheumatoid arthritis, acquired immunodeficiency syndrome (AIDS), and malignancies. Since red blood cell transfusions carry an appreciable risk to small babies, recombinant human erythropoietin gives hope of providing a safer alternative means in the treatment or prevention of anaemia of prematurity in the near future.
Descriptors		ANEMIA ERYTHROPOIETIN INFANT, PREMATURE INFANT, NEWBORN INFANT, LOW BIRTH WEIGHT